US2014161795A1PendingUtilityA1

Method for treating a disease characterized by increased appetite

33
Assignee: TAKEDA PHARMACEUTICALPriority: Sep 7, 2007Filed: Jul 24, 2013Published: Jun 12, 2014
Est. expirySep 7, 2027(~1.1 yrs left)· nominal 20-yr term from priority
Inventors:Johannes GrosseHelen HeffronKate Day
A61P 37/04A61P 3/04A61P 43/00A61P 3/10A61K 39/3955A61P 1/10A61P 1/00A61P 1/12A61K 38/2221A61P 1/04A61P 1/14
33
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Insl5 has been found to be orexigenic, i.e. it increases appetite. Insl5, or a derivative or fragment thereof that retains the ability to bind to the GPR100 receptor, or an Insl5 antibody, are useful in therapy, in particular to treat anorexia nervosa, bulimia, cachexia or wasting disease.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A method for treating a disease characterized by increased appetite, comprising administering an Insl5 antibody to a subject suffering from the disease. 
     
     
         2 . The method according to  claim 1 , wherein the disease is obesity. 
     
     
         3 . The method according to  claim 1 , wherein the method further comprises administering a Ghrelin antibody to the subject. 
     
     
         4 . The method according to  claim 3 , wherein the Insl5 antibody and the Ghrelin antibody are administered in the same composition. 
     
     
         5 . The method according to  claim 1 , wherein the Insl5 antibody is an antibody fragment. 
     
     
         6 . The method according to  claim 1 , wherein the Insl5 antibody is a monoclonal antibody. 
     
     
         7 . The method according to  claim 1 , wherein the Insl5 antibody is a humanized antibody.

Join the waitlist — get patent alerts

Track US2014161795A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.